Skip to search formSkip to main contentSkip to account menu

DNA-dependent Protein Kinase Inhibitor VX-984

Known as: DNA-PK Inhibitor VX-984, VX-984, VX984 
An ATP-competitive inhibitor of the catalytic subunit of DNA-dependent protein kinase (DNA-PK), with potential sensitizing and enhancing activities… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
VX-984 is a selective inhibitor of non-homologous end joining, with possible preferential activity in transformed cells
Purpose DNA double-strand breaks (DSBs) can be repaired by non-homologous end joining (NHEJ) or homologous recombination (HR). We… 
2017
2017
Abstract P5-06-05: Preclinical characterization of VX-984, a selective DNA-dependent protein kinase (DNA-PK) inhibitor in combination with doxorubicin in breast and ovarian cancers
Background: The efficacy of chemotherapeutic agents such as doxorubicin, which cause lethal DNA double-strand breaks (DSBs), is… 
2017
2017
Merck KGaA lands four Vertex cancer programs
Vertex Pharmaceuticals, the Boston-based biotech known for developing novel cystic fibrosis drugs, has licensed four R&D cancer… 
2016
2016
Abstract 3716: Potent radiation enhancement with VX-984, a selective DNA-PKcs inhibitor for the treatment of NSCLC
Ionizing radiation (IR), which is widely used for the treatment of cancer, causes double-strand breaks (DSBs) in DNA. If left… 
2016
2016
Preclinical characterization of the selective DNA-dependent protein kinase (DNA-PK) inhibitor VX-984 in combination with chemotherapy
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)